Genzyme said today that a draft consent decree sent by regulators would force it to hand over $175 million in profits earned from drugs made at its troubled Allston Landing manufacturing facility--a figure most investors seemed to find rather mild. Regulators also laid out a penalty of 18.5 percent of sales on products if it can't meet a set of deadlines for moving its fill/finish process out of the facility. Report
Virtual Clinical Trials Summit
Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials
In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.
